GLPI-103 — Regulatory Dossier: Reader's Guide

Every document, explained

Module 1 — Regional & Administrative

• Module 1 — Administrative Documents & Certifications Index — GLPI-103 — The index and cover layer of CTD Module 1 — the region-specific administrative forms, certifications, and references that sit in front of the scientific dossier.
• US NDA — Form FDA 356h, Cover Letter & Certifications — GLPI-103 — The executed-style US marketing-application forms: Form FDA 356h, the submission cover letter, and the financial-disclosure, debarment, environmental, patent, and user-fee certifications.
• EU MAA — Application Form (eAF) & Cover Letter — GLPI-103 — The executed-style EU centralised Marketing Authorisation Application form (eAF) and cover letter.
• MFDS 품목허가신청서 & 표지서한 — GLPI-103 — The executed-style Korean marketing-authorisation application form (품목허가신청서) and cover letter (표지서한).
• US Investigational New Drug (IND) Application — Summary — GLPI-103 — A summary of the US Investigational New Drug (IND) application — the package a sponsor files with the FDA before dosing humans in the US.
• Module 1 (US) — Administrative & US Prescribing Information — GLPI-103 — The US administrative content plus the US Prescribing Information (USPI) — the FDA-format drug label.
• FDA Risk Management & REMS Assessment — GLPI-103 — The FDA risk-management assessment and REMS (Risk Evaluation and Mitigation Strategy) analysis — whether extra safety controls beyond labeling are needed.
• EU Investigational Medicinal Product Dossier (IMPD) — Summary — GLPI-103 — A summary of the EU Investigational Medicinal Product Dossier (IMPD) — the European counterpart to the information supporting a clinical-trial application.
• Module 1 (EU) — Administrative & Summary of Product Characteristics — GLPI-103 — The EU administrative content plus the Summary of Product Characteristics (SmPC) — the European drug label.
• EU Risk Management Plan (EU-RMP) — GLPI-103 — The EU Risk Management Plan — a structured description of a medicine's safety profile and how its risks will be characterized and minimized.
• 임상시험계획승인신청(IND) 요약 — GLPI-103 (MFDS) — A summary of the Korean clinical-trial application (IND) filed with the MFDS (Ministry of Food and Drug Safety).
• Module 1 (Korea) — 행정정보 및 허가사항(라벨) — GLPI-103 — The Korean administrative content and the Korean product label (허가사항).
• MFDS Risk Management Plan (위해성 관리 계획, RMP) — GLPI-103 — The Korean Risk Management Plan (위해성 관리 계획) filed with the MFDS.
• Pediatric Plan (US PSP / EU PIP) — GLPI-103 — The pediatric development plan — the US Pediatric Study Plan (PSP) and the EU Paediatric Investigation Plan (PIP).
• Pre-IND Meeting Briefing Document — GLPI-103 — The briefing book for a Pre-IND meeting with the FDA — the questions and supporting summary a sponsor sends before that meeting.
• End-of-Phase-2 (EOP2) Meeting Briefing Document — GLPI-103 — The briefing book for the End-of-Phase-2 (EOP2) meeting with the FDA.
• Pre-NDA Meeting Briefing Document — GLPI-103 — The briefing book for the Pre-NDA/Pre-BLA meeting with the FDA.
• Expedited Program Designation Requests — GLPI-103 — Requests for expedited-program designations (e.g., Fast Track, Breakthrough Therapy, Priority Review) and their rationale.
• Development Safety Update Report (DSUR) — GLPI-103 — The Development Safety Update Report — the annual safety report while a drug is still in clinical development.
• Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — GLPI-103 — The Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — the periodic post-approval safety and benefit-risk review.
• Signal Management Plan — GLPI-103 — The signal-management plan — how potential new safety signals are detected, prioritized, evaluated, and acted on.

Module 2 — CTD Summaries & Overviews

• Module 2.1 — CTD Table of Contents — The CTD table of contents for the whole submission — the map of Modules 2 through 5.
• Module 2.2 — Introduction — A one-page introduction to the product: its pharmacologic class, proposed indication, and dosage form.
• Module 2.3 — Quality Overall Summary (QOS) — GLPI-103 — The Quality Overall Summary — the high-level synopsis of the chemistry, manufacturing, and controls (Module 3).
• Module 2.4 — Nonclinical Overview — The Nonclinical Overview — an integrated, interpretive appraisal of the animal pharmacology, PK, and toxicology.
• Module 2.5 — Clinical Overview — The Clinical Overview — a short, interpretive appraisal of the clinical evidence written for regulators.
• Module 2.5.6 — Benefits and Risks Conclusions — The structured Benefits and Risks conclusions section of the Clinical Overview.
• Module 2.6 — Nonclinical Written & Tabulated Summaries — The Nonclinical Written and Tabulated Summaries — the factual condensation of the Module 4 animal studies.
• Module 2.7.1 — Summary of Biopharmaceutic Studies & Analytical Methods — The Summary of Biopharmaceutic Studies and associated analytical methods (bioavailability, bioequivalence, formulation).
• Module 2.7.2 — Summary of Clinical Pharmacology Studies — The Summary of Clinical Pharmacology — human PK/PD, dose-exposure-response, and special-population and QT findings.
• Module 2.7.3 — Summary of Clinical Efficacy — The Summary of Clinical Efficacy — the integrated, cross-study account of how well the drug works.
• Module 2.7.4 — Summary of Clinical Safety — The Summary of Clinical Safety — the integrated safety picture across exposure, adverse events, special-interest events, deaths, and labs.
• Module 2.7.5 — Literature References — The list of literature references cited across the clinical summaries.
• Module 2.7.6 — Synopses of Individual Studies — Structured synopses of each individual clinical study in the program.

Module 3 — Quality (CMC)

• Module 3 — Quality (CMC) — GLPI-103 — The Module 3 (Quality / CMC) index and overview tying together the drug substance, drug product, and supporting quality sections.
• Module 3.2.S — Drug Substance (Full) — GLPI-103 — Module 3.2.S — the full drug substance (active ingredient) section: manufacture, characterization, control, and stability.
• Module 3.2.P — Drug Product (Full) — GLPI-103 — Module 3.2.P — the full drug product (finished dosage form) section: formulation, manufacture, control, and stability.
• Quality Target Product Profile (QTPP) & Critical Quality Attributes (CQA) — GLPI-103 — The Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs).
• Control Strategy — GLPI-103 — The control strategy — the planned set of controls that assure the product consistently meets its quality attributes.
• Process Development & Validation Summary — GLPI-103 — The process development and validation summary — evidence the commercial manufacturing process reliably produces conforming product.
• Analytical Methods & Validation Summary — GLPI-103 — The analytical methods and their validation — the test methods used to measure identity, purity, potency, and impurities.
• Stability Summary — GLPI-103 — The stability summary — how the substance and product change over time and the resulting shelf life and storage conditions.
• Module 3.2.A Appendices & 3.2.R Regional Information — GLPI-103 — Module 3.2.A appendices (e.g., facilities, adventitious-agent safety) and 3.2.R regional quality information.

Module 4 — Nonclinical (Animal) Study Reports

• Module 4 — Nonclinical Study Reports (Index & Stubs) — GLPI-103 — The Module 4 index and study-report stubs — the map of the animal pharmacology, PK, and toxicology reports.
• Module 4.2.1 — Pharmacology Study Reports — GLPI-103 — Module 4.2.1 — the pharmacology study reports: primary (does it work), secondary, and safety pharmacology.
• Module 4.2.2 — Pharmacokinetic Study Reports — GLPI-103 — Module 4.2.2 — the nonclinical pharmacokinetic study reports (absorption, distribution, metabolism, excretion, and toxicokinetics).
• Module 4.2.3 — Toxicology Study Reports — GLPI-103 — Module 4.2.3 — the toxicology study reports: single- and repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive, and other studies.
• Nonclinical Data Reviewer's Guide (nSDRG) — SEND — GLPI-103 — The Nonclinical Data Reviewer's Guide (nSDRG) for the SEND datasets — the animal-study equivalent of the clinical reviewer's guides.

Module 5 — Clinical Study Reports & Data

• Clinical Study Protocol — GLPI103-301 — The full Phase 3 clinical study protocol — the design, eligibility, treatments, endpoints, estimands, and visit schedule, fixed before any data exist.
• Statistical Analysis Plan — GLPI103-301 — The Statistical Analysis Plan — exactly how the trial will be analysed, locked before the blind is broken.
• Statistical Analysis Report — GLPI103-301 — The Statistical Analysis Report — the narrative synthesis of every statistical analysis actually run, with the methods and results laid out end to end.
• ADaM Dataset Specification — GLPI103-301 — The ADaM dataset specification — the variable-by-variable definition of the analysis datasets (e.g., ADSL, ADLB).
• Tables, Listings & Figures (TLF) Shells — GLPI103-301 — The Tables, Listings, and Figures (TLF) shells — the empty, pre-specified templates of every output the report will contain.
• Clinical Study Report — GLPI103-301 — The full Clinical Study Report for the pivotal Phase 3 study — the definitive account of disposition, efficacy, and safety.
• Patient Narratives (CSR Appendix 16.3) — GLPI103-301 — The written patient narratives for every death, serious adverse event, and adverse-event discontinuation in the pivotal trial — the ICH E3 §16.3 appendix to the CSR.
• Clinical Study Report (Abbreviated) — GLPI103-101 (FIH / SAD) — An abbreviated clinical study report for the first-in-human single-ascending-dose (SAD) study.
• Clinical Study Report (Abbreviated) — GLPI103-102 (MAD / early efficacy) — An abbreviated clinical study report for the multiple-ascending-dose (MAD) study with early efficacy signals.
• Clinical Study Report (Abbreviated) — GLPI103-201 (Phase 2 PoC / dose-finding) — An abbreviated clinical study report for the Phase 2 proof-of-concept / dose-finding study.
• Biopharmaceutic Study Reports (Module 5.3.1) — GLPI-103 — The biopharmaceutic study reports — absolute/relative bioavailability, food and dosing-condition effects, and the bridge between the IV and oral forms.
• Human Pharmacokinetic Study Reports (Module 5.3.3) — GLPI-103 — The human PK evidence — single/multiple-dose PK, population PK and exposure–response, and hepatic-, renal-impairment and drug–drug-interaction studies.
• Human Pharmacodynamic & Cardiac-Safety (QT) Study Reports (Module 5.3.4) — GLPI-103 — The human PD (biomarker) evidence and the ICH E14 cardiac-safety (thorough-QT / concentration–QTc) assessment.
• Immunogenicity Summary Report — GLPI-103 — The integrated immunogenicity assessment — anti-drug-antibody incidence, titre, neutralizing status, and impact on PK, efficacy, and safety.
• Bioanalytical Method Validation Summary — GLPI-103 — The validation of the PK (LC–MS/MS) assay and the tiered anti-drug-antibody assay to ICH M10.
• Investigator's Brochure — GLPI-103 — The Investigator's Brochure — the compiled nonclinical and clinical information given to trial investigators.
• Integrated Summary of Efficacy (ISE) — GLPI-103 — The Integrated Summary of Efficacy — a pooled analysis of efficacy across all relevant studies (an FDA requirement distinct from Module 2.7.3).
• Integrated Summary of Safety (ISS) — GLPI-103 — The Integrated Summary of Safety — a pooled analysis of safety across all studies and exposures.
• Module 5.2 — Tabular Listing of All Clinical Studies — Module 5.2 — the tabular listing of all clinical studies in the program.
• Blank Case Report Form (CRF) — GLPI103-301 — The blank Case Report Form — the data-collection form used at each visit to record trial data.
• Annotated Case Report Form (aCRF) — GLPI103-301 — The annotated Case Report Form (aCRF) — the CRF marked up to show which SDTM dataset and variable each field maps to.
• Study Data Reviewer's Guide (SDRG) — GLPI103-301 — The Study Data Reviewer's Guide (SDRG) — the human-readable guide to the SDTM (collected) datasets.
• Analysis Data Reviewer's Guide (ADRG) — GLPI103-301 — The Analysis Data Reviewer's Guide (ADRG) — the human-readable guide to the ADaM (analysis) datasets.
• Analysis Results Metadata (ARM) — GLPI103-301 — The Analysis Results Metadata — machine-readable metadata linking each key analysis result to the dataset, method, and code that produced it.
• CDISC Conformance Validation Report — GLPI103-301 — The CDISC conformance validation report — the results of checking the datasets against the SDTM/ADaM standards.

Trial Master File — how the trial is run

• Informed Consent Form (ICF) — GLPI103-301 (template) — The Informed Consent Form template — the document a subject reads and signs before joining the trial.
• Data Management Plan (DMP) — GLPI103-301 — The Data Management Plan — how trial data are collected, cleaned, coded, and locked.
• Clinical Monitoring Plan (CMP) — GLPI103-301 — The Clinical Monitoring Plan — how sites are monitored to protect subjects and data quality.
• Data Safety Monitoring Board (DSMB) Charter — GLPI103-301 — The Data Safety Monitoring Board charter — the mandate and procedures of the independent board overseeing subject safety.
• Randomization & IWRS Specification + UAT — GLPI103-301 — The randomization and IWRS specification (plus user-acceptance testing) — how subjects are assigned to treatments and how the system is validated.
• Safety Management Plan (SMP) — GLPI103-301 — The Safety Management Plan — how adverse events are collected, assessed, and reported during the trial.
• DSMB Meeting Minutes (Summary) — GLPI103-301 — Summary minutes of a DSMB meeting.
• Pharmacy / IMP Manual — GLPI103-301 — The Pharmacy / Investigational Medicinal Product manual — how the study drug is received, stored, prepared, and dispensed at sites.
• Central Laboratory Manual — GLPI103-301 — The central laboratory manual — how samples are collected, handled, shipped, and analysed.
• Clinical Trial Agreement (CTA) & IRB/IEC Approval Tracker — GLPI103-301 — The Clinical Trial Agreement (CTA) and the IRB/IEC approval tracker.

Program Management

• Project Charter — GLPI-103 Development Program — The project charter — the founding document authorizing the development program and defining its objectives, scope, and governance.
• Integrated Program Timeline & Milestones — GLPI-103 — The integrated program timeline and milestones — the schedule from nonclinical through submission.
• Clinical Program Budget & Cost Model — GLPI-103 — The clinical program budget and cost model.
• Project Risk Register — GLPI-103 Development Program — The project risk register — the catalogue of program risks with their likelihood, impact, and mitigations.
• Governance & RACI / Phase-Gate Criteria — GLPI-103 — The governance model, RACI matrix, and phase-gate criteria.
• Resource & Vendor (CRO) Management Plan — GLPI-103 — The resource and vendor / CRO management plan — how outsourced work is selected and overseen.
• Clinical Development Plan (CDP) — GLPI-103 — The Clinical Development Plan — the strategic roadmap of studies from first-in-human to registration and beyond.

Quality

• Quality Management Plan (QMP) — GLPI103-301 Program — The Quality Management Plan — how quality is designed into and assured across the program.
• Protocol Deviation Log — GLPI103-301 — The protocol deviation log — the record of departures from the protocol and their significance.
• Issue & CAPA Log — GLPI-103 Program — The issue and CAPA (Corrective and Preventive Action) log.
• Decision & Action-Item Log — GLPI-103 Program — The decision and action-item log — the record of key program decisions and their rationale.

---

Portfolio project. The drug, sponsor, and data are fictional; the standards, methods, and document structure are real.